MX9701067A - Sale unit for the parenteral application, device for the realization of the parenteral application such as filling unit of the previous sale unit.
- Google Patents
Sale unit for the parenteral application, device for the realization of the parenteral application such as filling unit of the previous sale unit.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer GmbhfiledCriticalRhone Poulenc Rorer Gmbh
Priority to MXPA/A/1997/001067ApriorityCriticalpatent/MXPA97001067A/en
Priority claimed from MXPA/A/1997/001067Aexternal-prioritypatent/MXPA97001067A/en
Publication of MX9701067ApublicationCriticalpatent/MX9701067A/en
Publication of MXPA97001067ApublicationCriticalpatent/MXPA97001067A/en
Sale unit for the parental application of liquid pharmaceutical products by means of the user, characterized in that in the union there are at least a cannula corresponding to the individual dosage number, a device for administering a predetermined amount of liquid of the pharmaceutical product in individual dosage like this at least a recipient full of the liquid product that is placed in the device and that by means of the device can be emptied by individual dosages, each individual dosage corresponding to the predetermined liquid amount of the pharmaceutical product. Equally contemplates devices and filling units.
MXPA/A/1997/001067A1997-02-11Sales unit for parenteral application, device for the realization of the parenteral application as filling unit for the anterior sale unit
MXPA97001067A
(en)
Dosage form comprising firstly a drug and a carboxymethylcellulose and secondly a carboxymethylcellulose of greater molecular weight than the first which co-operate when in contact with fluid to expel the drug
Significantly increased frequency of baseline IgA anti-type II collagen positivity in the placebo group in a study of oral type II collagen treatment of rheumatoid arthritis: comment on the article by Barnett et al